Brief: Nanoviricides Says Data Shows Pan-Coronavirus Nanopviricide Drug Candidate NV-Cov-2-R Minimizes Loss Of Remdesivir To Bodily Metabolism

NanoViricides,

21/09/2021 16:37

Sept 21 (Reuters) - NanoViricides Inc  NNVC.A :
    * NANOVIRICIDES INC SAYS DATA SHOWS PAN-CORONAVIRUS
NANOPVIRICIDE
DRUG CANDIDATE NV-COV-2-R MINIMIZES LOSS OF REMDESIVIR TO BODILY
METABOLISM
    * NANOVIRICIDES - ANTICIPATES STABILIZING EFFECT SHOULD LEAD
TO
HIGHLY EFFECTIVE PAN-CORONAVIRUS DRUG COULD POTENTIALLY CURE
MOST CASES OF COVID-19 INFECTION
    * NANOVIRICIDES - NV-COV-2-R IS EXPECTED TO CONTINUE TO BE
ACTIVE
IN SPITE OF EVOLUTION OF NOVEL VARIANTS OF SARS-COV-2
    * NANOVIRICIDES - BOTH NV-COV-2 AND REMDESIVIR ARE EXPECTED
TO
RETAIN THEIR EFFECTIVENESS AGAINST VARIANTS OF SARS-COV-2
    * NANOVIRICIDES SAYS NV-COV-2 HAS SHOWN EFFECTIVENESS
AGAINST
MULTIPLE UNRELATED CORONAVIRUS TYPES


Further company coverage:  NNVC.A 

 ((Reuters.Briefs@thomsonreuters.com;))